---
title: "BUZZ-Analysts see risks for elective-procedure medtechs after HCA cuts profit forecast"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292748150.md"
datetime: "2026-07-15T10:11:19.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292748150.md)
  - [en](https://longbridge.com/en/news/292748150.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292748150.md)
---

# BUZZ-Analysts see risks for elective-procedure medtechs after HCA cuts profit forecast

RBC Capital Markets says medical device makers with significant elective procedure exposure could face pressure heading into second-quarter earnings after HCA Healthcare’s (HCA.N) warning on weaker surgical volumes and rising uninsured patient levels

RBC’s discussions with the CFO of a Massachusetts-based hospital pointed to procedure volumes running about 5% lower over the past three months, driven largely by delayed elective surgeries, especially orthopedics

Brokerage sees Zimmer Biomet (ZBH.N) as most exposed due to its orthopedic focus, while Intuitive Surgical (ISRG.O) , GE HealthCare (GEHC.O) and Stryker (SYK.N) could also face headwinds from weaker hospital capital spending

RBC says electrophysiology, interventional cardiology and structural heart procedures remain relatively resilient, favoring names such as Johnson & Johnson (JNJ.N) , Edwards Lifesciences (EW.N) , Abbott (ABT.N) , Boston Scientific (BSX.N) and Medtronic (MDT.N)

HCA’s warning weighed on device stocks on Tuesday, with ISRG down 6.8%, SYK down 6.2%, MDT down 5.1%, BSX down 4.5%, Abbott down 3.4% and ZBH down 3.2%

Citi’s survey of 40 hospital executives showed about 70% reported ACA-related volume headwinds in Q2, but 86% expect deferred patients to return in the H2 2026, suggesting pressure may be temporary rather than structural

### Related Stocks

- [HCA.US](https://longbridge.com/en/quote/HCA.US.md)
- [ISRG.US](https://longbridge.com/en/quote/ISRG.US.md)
- [JNJ.US](https://longbridge.com/en/quote/JNJ.US.md)
- [ZBH.US](https://longbridge.com/en/quote/ZBH.US.md)
- [ISUL.US](https://longbridge.com/en/quote/ISUL.US.md)
- [GEHC.US](https://longbridge.com/en/quote/GEHC.US.md)
- [SYK.US](https://longbridge.com/en/quote/SYK.US.md)
- [EW.US](https://longbridge.com/en/quote/EW.US.md)
- [ABT.US](https://longbridge.com/en/quote/ABT.US.md)
- [BSX.US](https://longbridge.com/en/quote/BSX.US.md)
- [MDT.US](https://longbridge.com/en/quote/MDT.US.md)

## Related News & Research

- [Is It Too Late to Buy Johnson & Johnson After Its Blowout Earnings Report?](https://longbridge.com/en/news/293134734.md)
- [HCA Healthcare Posts Solid Q2 2026 Results, Trims Outlook](https://longbridge.com/en/news/293756146.md)
- [J&J Finally Has a Rival to da Vinci. 1 Number in Intuitive Surgical’s Last Quarter Says It Won’t Be Enough to Move the Needle for JNJ Stock.](https://longbridge.com/en/news/293657649.md)
- [HCA Healthcare Trims FY26 EPS Outlook - Update](https://longbridge.com/en/news/293753468.md)
- [HCA: Revenue up 8.7% in Q2 2026, but payer mix shifts and lower surgeries pressured margins](https://longbridge.com/en/news/293750898.md)